Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls
- 84 Downloads
A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13–1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94–1.71), for 1–8 years 1.41 (1.09–1.81), and less than 1 year (nonsurvivors) 1.94 (0.88–4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.
KeywordsApolipoprotein E End-stage renal disease Polymorphism
The project was supported by project no. NR 7958-5, IGA MH Czech Republic. The HAPIEE study is funded by the Wellcome Trust and the U.S. National Institute of Aging. We thank the participating clinicians (P. Táborský, FMC Prague; V. Polakovič and M. Sezamová, VFN Prague 6; E. Svítilová, Ústí nad Labem; J. Vlasák and I. Sojková, FMC Sokolov; M. Ryba, Liberec; P. Knetl, Jihlava; M. Ullrych, Děčín; R. Drahozal, Dialcorp Prague; V. Pavuková, Chomutov; B. Pavlíková, Uherské Hradiště; D. Fischlová, Kladno; M. Mokrejšová, VFN Prague; H. Chmelíčková, Třebíč; E. Pauchová, Prachatice; P. Vyskočil, Louny; Z. Nýdlová, Strakonice; J. Kopenec, Benešov; P. Fixa, Hradec Králové; J. Hajný, Chrudim; P. Bubeníček and P. Syrovátka, IKEM Prague; J. Zahálková, Olomouc; S. Šurel, Brno; Z. Hobzek, Písek; A. Hrubý, FMC Slavkov; J. Suchanová, Tábor; S. Vaňková, Eurocare Prague; J. Brabcová, Blansko) for collecting patient samples. We also thank workers in the National and Regional Institutes of Public Health who collected data on the population sample (controls).
- Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8:1–21Google Scholar
- Hubacek JA, Bloudíčková S, Bohuslavová R, Táborský P, Polakovic V, Sazamová M, Svítilová E, Vlasák J, Sojková I, Ryba M, Knetl P, Ullrych M, Drahozal R, Pavuková V, Pavlíková B, Fischlová D, Mokrejsová M, Chmelícková H, Pauchová E, Vyskocil P, Nýdlová Z, Kopenec J, Fixa P, Hajný J, Bubenícek P, Syrovátka P, Zahálková J, Surel S, Hobzek Z, Hrubý A, Suchanová J, Vanková S, Brabcová J, Viklický O, MIA Group (2007) Ghrelin variants influence development of body mass index and plasma levels of total cholesterol in dialyzed patients. Clin Chem Lab Med 45:1121–1123PubMedCrossRefGoogle Scholar
- Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A, Pikhart H, Nicholson A, Marmot M (2006) Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. BMC Public Health 6:255PubMedCrossRefGoogle Scholar
- Svobodova H, Kucera F, Stulc T, Vrablík M, Amartuvshin B, Altannavch Ts, Ceska R (2007) Apolipoprotein E gene polymorphism in the Mongolian population. Folia Biol (Praha) 53:138–142Google Scholar